Experience a better way to identify and quantitate host cell proteins and process-related impurities


Quick, effective, and efficient development processes are key to getting new biotherapeutics to market. You need total confidence in every step, but you also need speed. Agilent can help streamline your biotherapeutics development.
Automated and sensitive, our innovative analytical systems deliver accurate, reproducible results you can rely on.
Host cell protein (HCP) impurities pose a complex challenge. Since biopharmaceuticals are generated from biological sources, one challenge in their production is the large number of HCPs that need to be removed during the purification process. Even after multiple purification steps, some of the low-level HCPs may remain in the final products. Due to their potential to adversely impact product safety and efficacy, HCP levels must be monitored and controlled in drug products and are strictly regulated.
Traditionally, the enzyme-linked immunosorbent assay (ELISA) has been the standard method for quantifying HCPs in protein therapeutics. However, ELISA lacks the specificity and coverage to identify and quantify individual HCPs, which is an increasingly important need. Therefore, HPLC and LC/MS technologies are rapidly becoming the preferred choice for HCP analysis. The main challenge during HPLC and LC/MS analysis of HCPs was the coelution of low-abundance HCP peptides with the highly abundant peptides from the drug product. However, new HPLC, LC/MS, and column technologies are enabling better separation of peptides and ppm-level identification.
Count on innovative Agilent techniques and technologies to deliver reproducible analytical results, streamline your workflow, and increase speed, without sacrificing data quality or spectral resolution.
For Research Use Only. Not for use in diagnostic procedures.

Za odpiranje dokumenta
kliknite tukaj …

Comments are closed